135 related articles for article (PubMed ID: 12434715)
21. FDA notifications. FDA approves generic foscarnet sodium injection.
AIDS Alert; 2005 Jul; 20(7):82. PubMed ID: 16110563
[No Abstract] [Full Text] [Related]
22. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
23. Significant inhibitory effects of Hybridon's antisense compound on various HIV-1 replication steps in in vitro tests.
AIDS Patient Care STDS; 1996 Dec; 10(6):375-6. PubMed ID: 11361558
[No Abstract] [Full Text] [Related]
24. FDA approves cidofovir for treatment of CMV retinitis. Food and Drug Administration.
J Int Assoc Physicians AIDS Care; 1996 Aug; 2(8):30. PubMed ID: 11363758
[TBL] [Abstract][Full Text] [Related]
25. Cidofovir recommended for approval for CMV retinitis.
James JS
AIDS Treat News; 1996 Apr; (no 244):6-7. PubMed ID: 11363308
[TBL] [Abstract][Full Text] [Related]
26. FDA-Approved Oligonucleotide Therapies in 2017.
Stein CA; Castanotto D
Mol Ther; 2017 May; 25(5):1069-1075. PubMed ID: 28366767
[TBL] [Abstract][Full Text] [Related]
27. GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS.
Agrawal S; Tang JY
Antisense Res Dev; 1992; 2(4):261-6. PubMed ID: 1363378
[No Abstract] [Full Text] [Related]
28. FDA approves oral ganciclovir as first drug to prevent CMV disease. Food and Drug Administration.
Baker R
BETA; 1995 Dec; ():8. PubMed ID: 11363015
[TBL] [Abstract][Full Text] [Related]
29. Advances in CMV management: fomivirsen (Vitravene) approved.
Proj Inf Perspect; 1998 Dec; (26):7. PubMed ID: 11366499
[TBL] [Abstract][Full Text] [Related]
30. Still looking for the real GEM.
GMHC Treat Issues; 1996 Apr; 10(4):9. PubMed ID: 11363711
[TBL] [Abstract][Full Text] [Related]
31. New CMV drug won't replace other therapies.
AIDS Alert; 1998 Nov; 13(11):124-6. PubMed ID: 11365968
[TBL] [Abstract][Full Text] [Related]
32. First eye implant approved.
AIDS Alert; 1996 May; 11(5):59. PubMed ID: 11363254
[TBL] [Abstract][Full Text] [Related]
33. Isis presents data on safety and effectiveness of antisense CMV retinitis compound.
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50. PubMed ID: 11363533
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015.
Flores-Aguilar M; Besen G; Vuong C; Tatebayashi M; Munguia D; Gangan P; Wiley CA; Freeman WR
J Infect Dis; 1997 Jun; 175(6):1308-16. PubMed ID: 9180168
[TBL] [Abstract][Full Text] [Related]
35. Anti-CMV drug trials back on-line.
GMHC Treat Issues; 1996 May; 10(5):9. PubMed ID: 11363587
[TBL] [Abstract][Full Text] [Related]
36. [Antisense oligonucleotides with pharmacologic action].
Tauşer RG; Stoica O
Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):40-5. PubMed ID: 14755968
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligonucleotides in cutaneous therapy.
Wraight CJ; White PJ
Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
[TBL] [Abstract][Full Text] [Related]
38. Fomivirsen.
Highleyman L
BETA; 1998 Apr; ():29, 31. PubMed ID: 11365261
[TBL] [Abstract][Full Text] [Related]
39. Progress in antisense therapeutics discovery and development.
Crooke ST
Ciba Found Symp; 1997; 209():158-64; discussion 164-8. PubMed ID: 9383575
[TBL] [Abstract][Full Text] [Related]
40. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis.
de Smet MD; Meenken CJ; van den Horn GJ
Ocul Immunol Inflamm; 1999 Dec; 7(3-4):189-98. PubMed ID: 10611727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
